Veritas Genetics

Veritas Genetics was established in 2014 as a personal-genomics startup focused on making whole-genome sequencing and interpretation available to individuals. Its founding team included George M. Church, Mirza Cifric, Preston Estep, and Jonathan Zhao. The company was created at a time when sequencing technology was becoming less expensive, but the cost and complexity of translating a complete genome into understandable health information remained significant barriers for consumers. The company’s central proposition was broader than that of many targeted direct-to-consumer genetic tests. Rather than examining only a limited collection of markers, Veritas sought to sequence the full genome and provide interpretation across several health-related categories. Its communications emphasized inherited disease risk, with potential applications involving cancer predisposition, cardiovascular conditions, carrier status, and medication response. The model depended not only on laboratory sequencing but also on bioinformatic analysis and the presentation of results in a form intended for non-specialist users. Veritas became particularly visible because of its pricing strategy. Company statements described it as one of the early providers of whole-genome sequencing and interpretation below the $1,000 threshold. In 2018, it introduced myGenome, its flagship consumer-facing service. The offering was intended to give customers access to a broad set of genome-derived health findings rather than a narrow ancestry or trait report. A promotional price of $199 per order attracted considerable attention because it was far below the established price of many consumer whole-genome services at that time. The company’s profile increased further when CNBC placed it on the Disruptor 50 list in 2018 and again in 2019. These listings reflected the broader technology and healthcare interest in companies attempting to reduce the cost of genomic testing and integrate genetic information into consumer health management. By late 2019, Veritas was reassessing its business position. In December it announced that it was considering strategic options. In January 2020, the company announced that it had obtained additional funding and would resume its U.S. operations. The sequence of announcements indicated that its operating model was under pressure, although the available reference material does not provide detailed financial results or identify the precise terms of the funding. In March 2022, Veritas Genetics was acquired by LetsGetChecked, a global digital-health company. The transaction represented a shift from Veritas as an independent genomics startup to a business operating under the ownership of a larger health-testing platform. Available reference material does not document the post-acquisition product roadmap, leadership structure, or whether the Veritas brand continued as a standalone commercial operation. Accordingly, the brand’s current status cannot be confirmed from the supplied sources.

• 2022

  Acquired by LetsGetChecked

  [1]Veritas Geneticsen.wikipedia.org

  LetsGetChecked acquired Veritas Genetics.

• 2020

  U.S. operations resumed

  [1]Veritas Geneticsen.wikipedia.org

  Following additional funding, the company announced that it would resume operations in the United States.

• 2019

  Second CNBC Disruptor 50 appearance

  [1]Veritas Geneticsen.wikipedia.org

  The company appeared on the Disruptor 50 list for a second consecutive year.

• 2019

  Strategic review announced

  [1]Veritas Geneticsen.wikipedia.org

  Veritas announced that it was considering strategic options.

• 2018

  myGenome launched

  [1]Veritas Geneticsen.wikipedia.org

  The company launched myGenome, a whole-genome sequencing and interpretation service focused on inherited health risks and related genetic information.

• 2018

  CNBC Disruptor 50 recognition

  [1]Veritas Geneticsen.wikipedia.org

  Veritas Genetics was included on CNBC’s Disruptor 50 list.

• 2014

  Company founded

  [1]Veritas Geneticsen.wikipedia.org

  Veritas Genetics was co-founded by George M. Church, Mirza Cifric, Preston Estep, and Jonathan Zhao.

Accessible, consumer-oriented whole-genome sequencing with health-focused interpretation.

• Whole-genome sequencing and interpretation · 2018

  myGenome

  myGenome was Veritas Genetics’ flagship consumer offering, combining whole-genome sequencing with reports intended to explain medically relevant inherited genetic information. Reported areas included cancer risk, cardiovascular risk, carrier status, pharmacogenomics, and other findings. The service was positioned as a broad alternative to tests that examine only selected genetic variants.

• Genetic testing

  Whole-genome sequencing

  Veritas’ core service involved sequencing an individual’s complete genome and pairing the resulting data with interpretation. The company became known for attempting to make this type of testing available at consumer-oriented prices, including a reported $199 promotional offer during a period when full-genome services were generally more expensive.

• 2022

  Acquisition by LetsGetCheckedM&A

  Background

  Veritas Genetics had previously undergone a strategic review and operated in the expanding digital-health and consumer-testing market.

  Action taken

  LetsGetChecked acquired Veritas Genetics in March 2022.

  Aftermath

  Veritas became part of LetsGetChecked’s digital-health business. The supplied sources do not specify the purchase price, post-acquisition leadership, or the continuing status of the Veritas brand.

  Source

• 2019

  Announced consideration of strategic optionsStrategy

  Background

  Veritas disclosed that it was reviewing its strategic direction and possible alternatives.

  Action taken

  The company announced that it was considering strategic options.

  Aftermath

  In January 2020, Veritas announced additional funding and a plan to resume U.S. operations.

  Source

• 2018

  Introduced a $199 whole-genome sequencing promotionPrice change

  Background

  Veritas sought to demonstrate that whole-genome sequencing could be offered at a much lower consumer price than was customary at the time.

  Action taken

  The company offered whole-genome sequencing for $199 per order during a promotional period.

  Aftermath

  The offer attracted media attention and reinforced Veritas’ reputation as a price disruptor in personal genomics. The available sources do not establish the promotion’s duration or longer-term commercial results.

  Source

• 2018

  Launched myGenomeProduct launch

  Background

  Veritas aimed to move beyond limited-marker consumer testing by offering whole-genome sequencing paired with health-oriented interpretation.

  Action taken

  The company launched myGenome with reports addressing inherited cancer and cardiovascular risk, carrier status, pharmacogenomics, and other findings.

  Aftermath

  myGenome became the company’s flagship offering and the primary expression of its consumer whole-genome strategy.

  Source

1. 1Veritas Geneticsen.wikipedia.org
2. 2Veritas Genetics official websiteveritasgenetics.com